Proteasome inhibitors as reversers of resistance to artemisinin-based antimalarials [ 2015 - 2017 ]

Research Grant

Researchers: Prof Leann Tilley (Principal investigator) ,  Prof Susan Charman

Brief description Current antimalarial control is highly dependent on Artemisinin Combination Therapy (ACTs), which makes recent reports of decreased clinical efficacy of artemisinins extremely concerning. This project will develop proteasome inhibitors to synergise the activity of artemisinins - effectively reversing resistance. We will confirm that the selected compounds have good bioavailability, low cytotoxicity in human cell lines and efficacy in mouse models of malaria.

Funding Amount $AUD 473,534.34

Funding Scheme Development Grants

Notes Development Grant